Trial Profile
The utility of dynamic contrase-enhanced MRI for advanced and metastatic breast cancer administerd with bevacizumab
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 18 Sep 2018
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Paclitaxel
- Indications Advanced breast cancer
- Focus Pharmacodynamics
- 10 Sep 2018 Status changed from recruiting to completed.
- 14 May 2016 New trial record